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ABSTRACT
Aims: The prognostic stratification of patients with Idiopathic Dilated 
Cardiomyopathy (iDCM) is a difficult task. Here, we assessed the additive value of 
the evaluation of biomarkers of inflammasome activation and systemic inflammation 
for the long-term risk stratification of iDCM patients.
Methods and Results: We studied 156 ambulatory iDCM patients (mean age 58 
years, 77% men, 79% in NYHA class 1-2, median Left Ventricular Ejection Fraction 
(LVEF) 35%, mean sodium 139 mEq/L, median BNP 189 pg/mL, median IL-1 beta 
(IL-1β) 1.08 pg/mL, median IL-6 1.7 pg/mL and median IL-10 2.7 pg/mL).
During the follow-up period of 89.6 months, 35 patients (22%) died/underwent 
heart transplantation. Patients who died/underwent heart transplantation were more 
likely to be male, to be in NYHA class III, to have atrial fibrillation, to have lower 
LVEF and higher BNP levels. IL-1β, IL-6 and IL-10 levels did not differ significantly 
between the groups of patients with good or bad prognosis. IL-1β levels did not 
vary significantly among either the different NYHA classes or the quartiles of LVEF. 
In a multivariable model, however, IL-1β was a strong and independent predictor 
of all-cause mortality (HR 1.193, 95% CI 1.056 – 1.349, p=0.005 for log squared 
transformed values). Other factors associated with the outcome were: male gender, 
presence of atrial fibrillation and sodium concentration. The estimated time-dependent 
ROC curve of the multivariable model showed an AUC 0.74 (95% CI 0.65-0.86).
Conclusions: Serum levels of IL-1β could be useful to predict the long-term 
outcome of patients with iDCM.
INTRODUCTION
Idiopathic Dilated Cardiomyopathy (iDCM) is the 
most frequent indication for cardiac transplantation [1]. 
Being more prevalent in young adults, iDCM impairs 
the most productive working population and, due to its 
morbidity and frequent and prolonged requirement for 
hospitalization, it is tremendously expensive for both the 
national health system and the society in general [2].
Physicians need to counsel patients about prognosis 
to enable informed decisions about medication and life 
expectancy. However, given the heterogeneity of the 
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pathogenic mechanisms that lead to cardiac remodeling 
and heart failure, emerging mechanisms responsible for 
disease progression may help to identify and validate 
helpful biomarkers to prognostically stratify patients. 
In this regard, the sterile inflammatory response that 
occurs as a result of the activation of the inflammasome 
is an emerging mechanism responsible for promoting 
cardiac remodeling and heart failure (reviewed in [3]). 
Importantly, both experimental models and clinical 
studies have shown the involvement of the inflammasome 
in the evolution of both ischemic and non-ischemic heart 
disease. In line, a recent small clinical study suggests 
that the evaluation of the activation status of the NLRP3 
inflammasome may be employed to evaluate the short-
term outcome of patients affected by iDCM [4].
However, no literature data are available that 
evaluated the impact exerted by inflammasome activation 
on the long-term prognosis of iDCM patients. Therefore, 
we sought to assess the additive value of the evaluation of 
plasma biomarkers of inflammasome activation and systemic 
inflammation on top of traditional clinical variables for risk 
stratification of long-term mortality/heart transplantation in 
patients with heart failure affected by iDCM.
RESULTS
Study population
Patients had a median age of 58 years, 77% were 
male, and only 21% were in NYHA class III (being the 
remaining 79% in NYHA class I-II). Table 1 shows the 
demographic, clinical, and echocardiographic characteristics 
of 156 patients including the treatment, stratified by cardiac 
transplantation/mortality during the follow-up.
Biomarkers correlation with clinical and 
laboratory variables
With regard to IL-1β, we observed significant 
negative correlations between this cytokine levels and both 
LV mass (ρ=-0.21, p=0.037) and the presence of moderate-
severe mitral valve regurgitation (ρ=-0.18, p=0.023).
Additionally, BNP plasma concentration positively 
correlated with that of IL-6 (ρ=0.27, p=0.001).
Besides being positively correlated with BNP, IL-6 
was significantly positively correlated with the NYHA 
III functional class (ρ=0.20, p=0.012), and both with 
the LVEDV index (ρ=0.19, p=0.016) and the LVESV 
index (ρ=0.21, p=0.007). As opposed, IL-6 levels were 
negatively correlated with LVEF (ρ=-0.25, p=0.002).
Finally, IL-10 concentrations did not correlate 
significantly with any of the variables that we evaluated.
Long-term predictors of outcome
During the follow-up period (median 89.6 months, 
IQR 73.2-108.9), 35 patients (22%) died or underwent heart 
transplantation (31 deaths and 4 cardiac transplantations). 
Patients who died/underwent heart transplantation during 
the follow-up were more likely to be male, in NYHA class 
III, with atrial fibrillation and lower LV ejection fraction. 
The univariable analysis showed that these variables were 
even long-term predictors of outcome (Table 2). Among 
the biomarkers, BNP levels were significantly lower in 
survivors/non-transplanted patients versus patients who 
died/underwent cardiac transplantation. Importantly, we did 
not find a statistically significant difference in IL-1β levels 
between the groups that showed a different outcome during 
the follow-up (Table 1). However, BNP was not identified as 
a long-term predictor of outcome at the univariable analysis. 
On the contrary, IL-1β, while not having significantly 
different levels in the two groups of patients, was identified 
as a highly significant long-term predictor of outcome at 
univariate analysis (Table 2).
We did not observe a significant correlation between 
BNP and IL-1β, suggesting that these biomarkers assess 
different aspects of the heart failure syndrome. IL-1β 
levels did not vary significantly among either the different 
NYHA classes or the quartiles of LVEF (Figures 1 and 
2). In order to visualize the relationship between IL-
1β concentration and the prevalence of the composite 
outcome, we fitted a smoothed curve between logarithmic 
values of IL-1β and the frequency of the outcome, reported 
in Figure 3. We observed a low prevalence of outcome 
at low concentrations of ln (IL-1β) and then a steep 
increase in prevalence starting from 1 for ln (IL-1β). For 
this reason, we inserted in the final multivariable model a 
transformed version of ln (IL-1β), set at 0 for ln (IL-1β) < 
1, i.e. for original values of IL-1β lower than 2.7, and set at 
ln (IL-1β)**2 (square) for values greater or equal than 2.7.
In the final multivariable model (that includes 
clinically relevant variables as well as those variables 
with p < 0.1 at univariate analysis) were independently 
associated with long term mortality/cardiac transplantation 
the following variables: male gender, presence of atrial 
fibrillation, plasma sodium concentration and the transformed 
logarithmic squared version of IL-1β values (Table 2). The 
estimated time-dependent ROC curve of the multivariable 
model showed an AUC 0.74 (95% CI 0.65-0.86) with an 
horizon of the events fixed at 96 months (Figure 4).
DISCUSSION
This report represents the multicenter observational 
study with the largest cohort of real-life outpatients 
affected by heart failure secondary to iDCM in whom 
the long-term impact of inflammasome activation on 
mortality/need for cardiac transplantation has been 
described. The main finding of this study is that the 
prognostic information provided by the measurement of 
IL-1β plasma levels is independent of and beyond that 
provided by other relevant clinical factors, including the 
left ventricular ejection fraction as well as the degree of 
neurohumoral activation (sodium levels and plasma BNP).
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Table 1: Baseline characteristics of patients stratified by death/cardiac transplantation during the follow-up
All patients
(n= 156)
Alive
(78%; n=121)
M/HTx
(22%; n=35) p value
Age (years) 58 (50-67) 56 (50-63) 51 (37-61) 0.34
Male gender, n (%) 120 (77) 88 (73) 32 (91) 0.021
BMI (Kg/mq) 26 (24-29) 26 (24-29) 25 (23-30) 0.56
SBP (mmHg) 121 ± 17 122 ± 18 120 ± 13 0.67
DBP (mmHg) 78 ± 14 78 ± 15 77 ± 8 0.56
Heart Rate (bpm) 71 ± 14 70 ± 15 71 ± 10 0.82
Diabetic disease, n (%) 14 (9) 9 (7.4) 5 (14) 0.21
COPD, n (%) 13 (8.3) 8 (6.6) 5 (14.3) 0.15
Hb (g/dl) 14 (13-15) 14 (13.4-15) 14.4 (12.5-15.5) 0.69
Sodium (mEq/l) 139 ± 3 139 ± 3 138 ± 3 0.07
Creatinine (mg/dl) 1.12 ± 0.34 1.09 ± 0.26 1.24 ± 0.51 0.02
GFR, MDRD (ml/min/1.73 m2) 71 (59-91) 78 (60-91) 66 (59-93) 0.85
GFR ≤ 60 ml/min (%) 43 (28) 28 (23) 15 (43) 0.022
Urea (mg/dl) 42 ± 14 42 ± 15 42 ± 9 0.97
NYHA III (%) 33 (21) 21 (17) 12 (34) 0.031
Atrial fibrillation, n (%) 19 (12) 11 (9.1) 8 (23) 0.03
LBBB, n (%) 62 (40) 46 (38) 16 (46) 0.41
LA diameter index mm/ m2 22 (19-25) 21 (18-24) 22 (18-26) 0.15
LA index Area (cm2) 12 (11-14) 12 (11-14) 14 (10-16) 0.32
LV EDD index (mm/ m2) 32 (28-36) 33 (29-36) 33 (30-39) 0.96
LV ESD index (mm/ m2) 25 (22-30) 25 (21-29) 28 (23-34) 0.009
LV EDV index (ml/ m2) 90 (67-106) 69 (55-98) 84 (67-104) 0.56
LV ESV index (ml/m2) 61 (39-75) 43 (30-65) 58 (36-73) 0.08
LVEF (%) 35 (27-42) 38 (31-46) 35 (24-46) 0.035
MR moderate-severe n (%) 77 (49) 57 (47) 20 (57) 0.29
ACE inhibitors/ARBs, n (%) 146 (94) 112 (93) 34 (97) 0.33
Beta-blockers, n (%) 146 (94) 112 (93) 34 (97) 0.33
Diuretics, n (%) 117 (75) 89 (74) 28 (80) 0.44
Antiarrhythmics n (%) 62 (40) 47 (39) 15 (43) 0.67
Amiodarone n (%) 22 (14) 15 (12) 7 (20) 0.25
Digoxin, n (%) 56 (36) 42 (35) 14 (40) 0.57
Antiplatelet, n (%) 53 (34) 41 (34) 12 (34) 0.96
(Continued )
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All patients
(n= 156)
Alive
(78%; n=121)
M/HTx
(22%; n=35) p value
Anticoagulant, n (%) 44 (28) 30 (25) 14 (40) 0.08
Hypolipidemic drugs, n (%) 51 (33) 43 (35) 8 (23) 0.16
Nitrates, n (%) 10 (6.4) 8 (6.6) 2 (5.7) 0.85
Oral antidiabetics, n (%) 7 (7.1) 5 (6.4) 2 (10) 0.58
ICD, n (%) 73 (47) 57 (47) 16 (46) 0.88
CRT, n (%) 32 (20) 23 (19) 9 (26) 0.39
CRT-D, n (%) 83 (53) 63 (52) 20 (57) 0.6
BNP (pg/ml) 189 (84-357) 181 (55-311) 258 (43-422) 0.004
IL-1 β (pg/mL) 1.08 (0.35-2.4) 0.77 (0.17-1.9) 0.67 (0.4-4.1) 0.38
IL-6 (pg/mL) 1.7 (0.6-4.4) 0.77 (0.14 –3.1) 1.5 (0.5-8.4) 0.18
IL-10 (pg/mL) 2.7 (0.5-11) 3 (0.8 – 9.1) 3.1 (1.4 -12) 0.34
Abbreviations: ACEI/ARBs: angiotensin converting enzyme inhibitors/angiotensin receptor blockers; BMI: body mass 
index; BNP: B-type natriuretic peptide; COPD: chronic obstructive pulmonary disease; CRT: cardiac resynchronization 
therapy; CRT-D: cardiac resynchronization therapy defibrillator; DBP: diastolic blood pressure; EDD: end-diastolic diameter; 
EDV: end-diastolic volume; ESD: end-systolic diameter; ESV: end-systolic volume; GFR: glomerular filtration rate; Hb: 
haemoglobin; ICD: implantable cardioverter defibrillator; IL: interleukin; LA: left atrium; LBBB: left bundle branch block; 
LV: left ventricular; LVEF: left ventricular ejection fraction; MDRD: Modification of Diet in Renal Disease; MR: mitral 
regurgitation; M/HTx: death/cardiac transplantation; NYHA: New York Heart Association; SBP: systolic blood pressure.
The progression of heart failure is complex 
and is driven by multiple biologic processes, such as 
neurohormonal activation and inflammation.
As introduced, an accumulating body of literature 
demonstrates the primary role played by inflammasome 
activation in the evolution of heart disease towards cardiac 
remodeling and heart failure. A recent work by Luo and 
collaborators has recently measured inflammasome 
components in peripheral blood mononuclear cells and 
IL-1β in the plasma of 54 iDCM patients and 20 healthy 
controls. The study showed that NLRP3 and IL-1β mRNA 
levels are independent predictors of the necessity for 
rehospitalization in a six month follow-up [4]. The current 
study significantly expands the findings of the previous 
cited study in ambulatory setting of larger cohort of 
patients with iDCM and with long-term follow-up. Our 
findings, that associate IL-1β levels with patient mortality/
necessity for transplantation, may have a therapeutic 
importance too, since the inhibition of the inflammasome/
IL-1β axis is being investigated as a promising target [5]. 
In line, a single intraperitoneal injection of IL-1β is able 
to repress the systolic function of healthy mice in a dose-
dependent fashion. Furthermore, the addition of Anakinra 
(the soluble IL-1 receptor antagonist) to IL-1β fully 
prevented systolic dysfunction [6].
With regard to possible comorbidities that may 
influence IL-1β levels diabetes [7], myocarditis [8] 
and other autoimmune diseases [9] are among the most 
investigated ones. In our case study, the frequency of 
diabetic patients did not differ among the groups with 
different outcome, nor it was significantly associated with 
outcome at univariate analysis. Furthermore, patients 
suffering from acute myocarditis or known autoimmune 
diseases were excluded from our analysis.
Along with IL-1β, we investigated also whether 
IL-6 plasma levels are able to predict the prognosis of 
patients affected by iDCM. IL-6 is a pleiotropic cytokine 
that has been shown to exert both protective actions (e.g. 
favoring the resolution of the neutrophilic infiltrate) and 
to participate to disease pathogenesis (e.g. promoting 
the monocyte infiltration). Studies conducted on iDCM 
patients have shown increased production of IL-6 [10]. 
However, in the iDCM setting, IL-6 levels are not clearly 
associated with left ventricular reverse remodeling or 
patients’ prognosis [11]. Our study is in line with these 
observations and shows that, although IL-6 levels are 
significantly correlated with important clinical parameters, 
it is not able to predict long term prognosis of patients.
In addition to inflammatory processes, the complex 
pathways of neurohormonal activation are observed 
and their quantification through biomarkers might relay 
important information about heart failure. In our study, 
serum sodium levels were independently associated with 
the long-term outcome. In the setting of heart failure, 
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hyponatremia reflects more severe activation of the 
renin–angiotensin–aldosterone and of the sympathetic 
nervous system as well as increased vasopressin release 
[12]. Also, hyponatriemia could be associated with the 
diuretic therapy, which enhances sodium excretion [12]. 
A recent meta-analysis [13], that included 14,766 patients 
from 22 studies and used as endpoint the death from 
any cause at three years, showed that the risk of death 
is linearly increasing with serum sodium levels < 140 
mmol/L. Natriuretic peptides, indicative of myocardial 
stretch, are well-recognized prognostic biomarkers in 
the setting of heart failure [14]. In our study, despite we 
observed significantly higher BNP levels at baseline in 
patients who died/underwent heart transplantation, BNP 
was not an independent predictor of long-term outcome at 
multivariate analysis; however the median levels of BNP 
Table 2: Univariate and multivariate analysis of factors correlated with long-term outcome
Univariate analysis Multivariate analysis
HR (95% C.I.) p value HR (95% C.I.) p value
Age 0.994 (0.971 – 1.018) 0.629 - -
Male gender 3.571 (1.093 – 11.670) 0.035 3.351 (1.013 – 11.089) 0.048
BMI 0.995 (0.920 – 1-076) 0.906 - -
NYHA 1.462 (0.960 – 2.227) 0.076 - -
NYHA III 2.343 (1.162 – 4.724) 0.017 - -
SPB 0.995 (0.975 – 1.014) 0.595 - -
HR 1.002 (0.979 – 1.026) 0.842 - -
Atrial fibrillation 2.634 (1.194 – 5.811) 0.016 2.564 (1.143 – 5.752) 0.022
LBBB 1.355 80.695 – 2.641) 0.372 - -
Hb 0.962 (0.787 – 1.177) 0.709 - -
Anemia 2.222 (1.083 – 4.557) 0.029 - -
Creatinine 2.007 (1.082 – 3.512) 0.027 - -
GFR MDRD 0.994 (0.978 – 1.010) 0.464 - -
GFR ≤ 60 ml/min 2.206 (1.129 – 4.311) 0.021 - -
Sodium 0.905 (0.812 – 1.009) 0.072 0.893 (0.798 – 0.999) 0.048
LV EDD index 1.011 (0.949 – 1.076) 0.745 - -
LVEF 0.968 (0.937 – 0.999) 0.044 - -
MR 1.184 (0.841 – 1.667) 0.333 - -
Moderate-severe MR 1.509 (0.770 – 2.956) 0.230 - -
ACE inhibitors/ARB 2.422 (0.332 – 17.699) 0.383 - -
Beta – blockers 2.389 (0.327 – 17.454) 0.391 - -
ICD 0.949 (0.488 – 1.846) 0.878 - -
CRT 1.449 (0.679 – 3.094) 0.338 - -
CRT-D 1.234 (0.631 – 2.411) 0.539 - -
BNP 1.001 (1.000 – 1.001) 0.135 - -
IL – 1β 1.069 (1.028 – 1.113) 0.001
1.193 (1.056 – 
1.349)**
0.005
IL – 6 1.000 (0.998 – 1.002) 0.991 - -
IL – 10 1.000 (0.998 – 1.001) 0.650 - -
Abbreviations: ACEI/ARBs: angiotensin converting enzyme inhibitors/angiotensin receptor blockers; BMI: body mass 
index; BNP: B-type natriuretic peptide; CRT: cardiac resynchronization therapy; CRT-D: cardiac resynchronization therapy 
defibrillator; EDD: end-diastolic diameter; GFR: glomerular filtration rate; Hb: haemoglobin; ICD: implantable cardioverter 
defibrillator; IL: interleukin; LBBB: left bundle branch block; LV: left ventricular; LVEF: left ventricular ejection fraction; 
MDRD: Modification of Diet in Renal Disease; MR: mitral regurgitation;; NYHA: New York Heart Association; SBP: systolic 
blood pressure.
**log squared transformed values.
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Figure 1: Levels of IL-1β in patients with NYHA functional class I to III. The bottom and top of the box represent the first and 
third quartiles, and the band inside the box is the median. Lines extending vertically from the boxes (whiskers) indicate variability outside 
the upper and lower quartiles, i.e. respectively the lowest value still within 1.5 IQR (interquartile range) of the lower quartile, and the 
highest value still within 1.5 IQR of the upper quartile.
Figure 2: Levels of IL-1β in patients as function of quartiles of LV ejection fraction. As in Figure 1, box plots of IL-1β values 
are depicted according to quartiles of LV ejection fraction. See Figure 1 legend for box plot explanation.
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Figure 3: Relationship between IL-1β concentration and outcome. Plot of smoothed estimates of (natural) log values of IL-1β 
concentration on the x-axis vs. rates of outcome on the y-axis. The “plsmo” function of the R library “Hmisc” has been used to generate the 
plot; locally-weighted polynomial regression is used to generate the depicted curve.
Figure 4: Time-dependent ROC curve of the multivariable model. Area under the Curve (AUC) with corresponding 95% CI 
(confidence interval) is depicted: to calculate AUC we used as a marker the risk of event estimated by the multivariable model and as time-
horizon events within 96 months of follow up. Inverse Probability of Censoring Weighting (IPCW) is used to account for the censoring 
mechanism. Technical details about time-dependent ROC computation can be found in [20].
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in both groups of our population were under the diagnostic 
threshold for heart failure. Several studies found that BNP 
levels are not always elevated, and the paradoxically low 
BNP level is an adverse prognostic marker in patients with 
advanced heart failure [15–17]. In the setting of patients 
with chronic stable heart failure, one recent systematic 
review [18] does not recommend to clinicians BNP or NT-
proBNP use for risk stratification of patients.
Study limitation
The present study focused primarily on the long-
term mortality/need for cardiac transplantation of patients 
with iDCM. We accept as a limitation that we could 
not provide information on the time-course of plasma 
biomarker levels since the blood sample for biomarker 
analysis was drawn only at baseline.
In conclusion, serum levels of IL-1β were able to 
prognostically stratify our cohort of iDCM patients. The 
precise cut-off of IL-1β associated with bad outcome in 
iDCM remains to be determined in larger, independent 
cohorts of patients.
MATERIALS AND METHODS
A cohort of 156 patients with iDCM referred to 
Cardiology of Trieste and Monzino was prospectively 
enrolled between March 30th, 2006 and January 31st, 2010 
(iDCM is a rare heart muscle disease with an incidence 
of 5 to 8 cases per 100,000 persons-year). The diagnosis 
of iDCM was made according to the World Health 
Organization criteria [19].
Clinical and instrumental data were collected at the 
moment of enrolment and during each follow-up visit. 
Patients had schedule of visits at six, 12, 24 months and, 
subsequently, every two years or more frequently on the 
base of specific clinical needs.
Blood samples were collected in 
ethylenediaminetetraacetic acid, immediately placed on 
ice, processed, and stored at -80°C until analysis was 
performed. The same blood sample was employed to test 
the concentrations of B-type natriuretic peptide (BNP), IL-
1β, Interleukin 6 (IL-6 ) and Interleukin 10 (IL-10). We 
tested BNP also, since natriuretic peptides are currently 
the benchmark against which all biomarkers for prognosis 
of patients with heart failure must be measured.
Determination of biomarkers
The quantitative determination of the BNP was 
measured from plasma samples obtained by centrifuging 
whole blood samples at 2,500g for 10’ at 4°C. Plasma 
levels of BNP were assayed using the competitive ELISA 
immunoassay RayBio (r) BNP Enzyme Immunoassay 
(RayBiotech, Inc., Norcross, GA), according to the 
manufacturer’s protocol. The minimum detectable 
concentration of BNP was: 1.66 pg/ml with an intra-assay 
coefficient of variation (CV) of < 10 % and an inter-assay 
CV of < 15 %.
For the determination of plasma levels of IL-1 β, a 
high-sensitivity ELISA kit (HS Quantikine Human IL-1 
β Immunoassay, R&D Systems, Inc, MN, USA) has been 
used. The minimum detectable dose of Il-1β ranged from 
0.023 to 0.140 pg/mL. The mean minimum detectable 
dose was 0,057 pg/mL. The concentration of IL-1β has 
been measured by subtracting the readings at 650nm from 
the readings at 450nm at the spectrophotometer.
IL-6 High sensitivity sandwich ELISA (Quantikine 
HS, R&D Systems, Minneapolis, MN) was used to 
measure IL-6 plasma levels. The minimum detectable 
dose was of 0.11 pg/mL while the kit’s range was 0.2 - 
10 pg/mL.
Plasma levels of IL-10 were measured with The 
Quantikine Human IL-10 Immunoassay solid phase ELISA 
(R&D Systems, Inc, MN, USA). This immunoassay has 
been shown to quantify recombinant human IL-10 and 
does not cross-react with viral IL-10. The optical density 
was determined at 450nm with wavelength correction at 
570 nm by using a microplate reader. The sensitivity of the 
test of human IL-10 was less than 3.9 pg/mL.
Follow-up and outcomes
The main endpoint was all-cause mortality/urgent 
heart transplantation. For the objective of our study urgent 
heart transplantation was considered in status I, indicated 
in patients with refractory heart failure with necessity 
of inotropic treatment and/or mechanical support of the 
circulation.
Information regarding the end-points were obtained 
directly from the patient, from their family doctor or 
from the registers of death of the communes of residence. 
The end of the follow-up was set to December 31st, 
2015 or the date of death or heart transplantation of the 
patient. This study conforms to the principles outlined 
in the Declaration of Helsinki and was approved by the 
institutional ethics committee. All patients provided 
written informed consent prior to enlistment in the 
Registry.
Statistical analysis
Characteristics of the study population are described 
using means ± s.d. or median and interquartile range for 
continuous variables, depending on the distribution’s 
shape, and percentages for categorical variables. Data 
were tested for normal distribution using the Kolmogorov-
Smirnov test. T-test or Mann-Whitney test, as appropriate, 
were used to compare continuous variables between two 
groups. For categorical variables, cross-tabulations were 
generated, and chi-square or Fisher exact test was used to 
compare distributions.
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To test the capacity of the biohumoral parameters to 
prognostically stratify iDCM patients, we analyzed death 
or necessity of cardiac transplantation as endpoint. Cox 
univariable analysis was performed and clinically relevant 
covariates as well as those with p < 0.1 were selected for 
multivariable analysis. Retention in the final stepwise 
model required the variable to be significant at p < 0.05 
at multivariate analysis. Results are presented as hazard 
ratios (HR) and 95% confidence intervals (95% CI). The 
proportional hazards assumption of the Cox model was 
checked using the Therneau and Grambsch test.
Since distributions of the biohumoral parameters 
showed a marked asymmetry, we performed a logarithmic 
transformation of their values and repeated the stepwise 
procedure using the log-transformed values. Log 
transformed data confirmed our findings on mortality/
cardiac transplantation.
Finally, the obtained score from the multivariable 
model was evaluated in terms of predictive accuracy by 
means of time-dependent ROC curve suitable for censored 
data [20]. Analyses were conducted with IBM-SPSS 21 
statistical software and the R package version 3.2.2, using 
libraries “survival”, “rms”, “Hmisc” and “timeROC”.
Abbreviations
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